Journal of Bioequivalence & Bioavailability

Rational design of amorphous solid dispersion for solubility and bioavailability enhancement

6^th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit

August 17-19, 2015 Chicago, USA

Jim Jingjun Huang

Keynote: J Bioequiv Availab

Abstract:

As a result of research efforts, solid dispersion dosage forms have been applied to several commercial pharmaceutical
products. It is expected that with better understanding of SD manufacturing process and molecular structure associated
with its in vitro/in vivo performance, there will be more SD dosage forms introduced into the market in the future. The aim of
this presentation is to evaluate effects of formulation and process technology on molecular dispersibility in solid dispersions
(SD). Solid dispersions prepared by different methods were characterized. A method was developed based on regular solution
and Flory-Huggins theories to calculate drug-polymer interaction parameter in solid dispersion systems. A synergic effect
of combined polymers on drug molecular dispersibility in solid dispersions was observed. Process methodology was also
found to play an important role in formation of amorphous SD. Since drug molecular dispersibility in combined polymer is a
result of interplay between thermodynamic and kinetic factors, drug molecular dispersions are thermodynamically metastable
systems. To explore those supersaturation systems for use in drug delivery of poorly water soluble drugs, it is critical to balance
drug-polymer interactions and matrix glass transition point and to consider a process technology with a fast solidification rate
during formulation and process development of amorphous SD.

Biography :

Jim Jingjun Huang received his PhD in Pharmaceutics from the University of the Sciences in Philadelphia under Joseph B. Schwartz. He has more than 15 years of
experience in preclinical and clinical formulation development and commercialization of a variety of oral and parenteral dosage forms during his tenure at Ascendia,
Roche, AstraZeneca, Baxter and Wyeth. He is currently CEO/CSO of Ascendia Pharmaceuticals. His publications include studies on solubilization and drug
delivery technologies of poorly water soluble drug. He has served as expert reviewer for several peer-review international journals. He is a member of American
Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).